Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs-Reference-Cited by-同舟云学术

Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs

Published:2023-09-04 Issue:1 Volume:26 Page:1169-1177
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Jesudian Arun B.¹^ORCID,Gagnon-Sanschagrin Patrick²^ORCID,Heimanson Zeev³,Bungay Rebecca²^ORCID,Chen Jingyi²,Guérin Annie²,Bumpass Brock⁴,Borroto Danellys⁴,Joseph George⁴⁵,Dashputre Ankur A.⁴^ORCID

Affiliation:

1. Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY, USA

2. Analysis Group, Inc, Montréal, Canada

3. Salix Pharmaceuticals, Bridgewater, NJ, USA

4. Bausch Health, Bridgewater, NJ, USA

5. BioNTech US Inc, Cambridge, MA, USA

Funder

Bausch Health US, LLC

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2255074

Reference36 articles.

1. Hepatic encephalopathy: an update on the pathophysiology and therapeutic options;Elwir S;J Clin Transl Hepatol,2017

2. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management

3. Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin

4. In-Hospital Mortality and Economic Burden Associated With Hepatic Encephalopathy in the United States From 2005 to 2009

5. Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correction;Journal of Medical Economics;2023-10-28